Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Aug 11, 2022 Abeona Therapeutics Reports Second Quarter 2022 Financial Results View Press Release Jul 20, 2022 Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements View Press Release Jun 6, 2022 Abeona Therapeutics to Present at the Jefferies Healthcare Conference View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
